Provectus Logo

Advancing a Winning Front
in the War Against Cancer

Provectus Biopharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. Our product pipeline includes:

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read our detailed Research Reports.

Legal Notice       ©2002-2014 Provectus Biopharmaceuticals, Inc.

Subscribe to the Provectus News newsletter

In The Media    

April 9, 2014

Investigational drug PV-10 decreases melanoma cells in tumors

An April 8, 2014 article in Dermatology Times reports on PV-10 study findings recently presented by Moffitt Cancer Center researchers at the 2014 AARC annual meeting.

April 3, 2014

BioCentury Reports News of Provectus' Request for Breakthrough Therapy Designation for PV-10 for Melanoma

The Clinical News section of the March 31, 2014 edition of BioCentury covered news of Provectus' recent submission of a request to the US FDA to grant Breakthrough Therapy Designation to PV-10 for the treatment of locally advanced cutaneous melanoma.

February 27, 2014

Provectus's PV-10 Path to Initial Approval in U.S. Now Clear Per FDA Meeting Minutes

Pharmacy Choice covers news that Provectus will submit a Breakthrough Therapy Designation request this quarter with the U.S. FDA to use PV-10 for the treatment of locally advanced cutaneous melanoma.

February 11, 2014

BioCentury reports that Provectus will request Breakthrough Therapy Designation for PV-10

The Clinical News section of the February 3rd edition of BioCentury covered news of Provectus' upcoming submission of a request to the US FDA to grant Breakthrough Therapy Designation to PV-10 for the treatment of locally advanced cutaneous melanoma.

February 3, 2014

Expert Review of Anticancer Therapy reports on Phase 1 study of PV-10 bystander effect

The News in Brief section of Expert Review of Anticancer Therapy Vol. 13, No. 9. reports on the Phase 1 clinical trial being performed at the H. Lee Moffitt Cancer Center to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

January 13, 2014

BioCentury covers news of Provectus' Type C meeting with FDA

The Week in Review - Company News section of the January 6th edition of BioCentury covered news of Provectus' December 16th Type C meeting with the FDA and that the FDA should issue meeting minutes by January 15th.


Press Releases    

April 21, 2014

Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania.

April 14, 2014

Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing.

April 7, 2014

Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA.

April 2, 2014

Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, www.pvct.com) Provectus announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014.

April 1, 2014

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com) Provectus announced today that data on treatment of cutaneous melanoma using its investigational drug PV-10 have been selected to be part of the Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting this year at McCormick Place, Chicago, IL, May 30-June 3, 2014.

April 1, 2014

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com) Provectus announced today that data on PV-10 for cutaneous melanoma will be included in a session at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference.